Why the study?
Is a rechallenge with fluoropyrimidines safe in patients who have experienced a previous cardiac adverse event?
Is a rechallenge with fluoropyrimidines safe in patients who have experienced a previous cardiac adverse event?
This case report highlights the clinical challenges and considerations for rechallenging patients with capecitabine after a prior fluoropyrimidine-induced cardiac adverse event.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for safe fluoropyrimidine rechallenge after cardiotoxicity; prospective data needed before practice change.
Fluoropyrimidines, such as capecitabine and 5-fluorouracil, may cause cardiac toxicity. In recent years, the incidence of this side effect has increased and it is expected to further rise due to the population aging and the disproportionate incidence of breast and gastrointestinal cancers in older individuals. The spectrum of cardiac manifestations includes different signs and symptoms and the diagnosis may be difficult. Here, we report the case of a 43-year-old woman with advanced breast cancer who was rechallenged with a capecitabine-based regimen after experiencing a cardiac adverse event during the first fluoropyrimidine exposure. This real-practice case serves as a springboard for discussion about the current evidence on differential diagnosis of capecitabine-related cardiac toxicity, its risk factors, and the underpinning mechanisms of early onset. Moreover, we discussed whether a rechallenge with fluoropyrimidines could be safe in patients who had experienced a previous cardiac adverse event.
No takes yet. Share an insight, caveat, or question.
Aprile et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: